EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes

Mariano Berro, Silvina Odstrcil, Milagros Frassa, Maria M Rivas, Jose I Trucco, Ines Paganini, Gustavo D Kusminsky, Daniel Couriel

Transplant Immunology · 2025

DOI: 10.1016/j.trim.2025.102181 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Transplant Immunology, 2025. Verfasst von Mariano Berro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Cell Transplant Unit, Hospital Universitario Austral, Derqui, Argentina. Electronic address: berromariano@hotmail.com. Hauptthemen laut MEDLINE: Tacrolimus, Immunosuppressive Agents, Graft Rejection, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus is a backbone for immunosuppression after allogeneic stem cell transplantation (AlloSCT). There is no sufficient kinetic data demonstrating the consistency of maintaining therapeutic levels. Herein, we measured the kinetic of therapeutic range (TTR) and its impact on outcomes of AlloSCT. Our local observational cohort included 186 adult AlloSCT performed at Hospital Austral between January 2012 and December 2019. An additional external cohort included 307 adult patients with AlloSCT from the University of Utah. We defined adequate TTR as >75 % of the measurements between 5.0 and 15.0 ng/mL during the first 30 days post-transplantation. In our local cohort, 55 % of patients had adequate TTR values. Primary graft failure was significantly lower in patients with adequate TTR (2 %, 95 % CI 0.5-7.7 % vs. 10 %, 95 % CI 5-18 %, p = 0.01). Non relapse mortality (NRM) was significantly lower with adequate TTR (17 %, 95 % CI 11-26 % vs. 33 %, 95 % CI 24-43 %; p < 0.01). Similarly, the external cohort had an NRM value significantly reduced in patients with adequate TTR values. In the pooled data analysis of local and external groups (n = 493), the TTR value below minimal range (≥25 % of measurements

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusImmunosuppressive AgentsGraft RejectionHematopoietic Stem Cell TransplantationHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAgedTransplantation, HomologousRetrospective StudiesGraft Survival

Stichwörter der Autor:innen

Graft failureNRMTTRTacrolimus

Substanzen

TacrolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Hematopoietic Cell Transplant Unit, Hospital Universitario Austral, Derqui, Argentina. Electronic address: berromariano@hotmail.com.
  • Hematopoietic Cell Transplant Unit, Hunstman Cancer Institute, University of Utah, USA.
  • Hematopoietic Cell Transplant Unit, Hospital Universitario Austral, Derqui, Argentina.

Zitieren

APA

Berro, M., Odstrcil, S., Frassa, M., Rivas, M. M., Trucco, J. I., Paganini, I., Kusminsky, G. D., & Couriel, D. (2025). Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes. Transplant Immunology. https://doi.org/10.1016/j.trim.2025.102181

Vancouver

Berro M, Odstrcil S, Frassa M, Rivas MM, Trucco JI, Paganini I, et al. Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes. Transplant Immunology. 2025. doi:10.1016/j.trim.2025.102181

BibTeX
@article{Berro2025,
  author = {Berro, Mariano and Odstrcil, Silvina and Frassa, Milagros and Rivas, Maria M and Trucco, Jose I and Paganini, Ines and Kusminsky, Gustavo D and Couriel, Daniel},
  title = {Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes},
  journal = {Transplant Immunology},
  year = {2025},
  doi = {10.1016/j.trim.2025.102181}
}
Kostenlos starten →